Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatme...
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
- Associated Therapies
- -
Breast Cancer Treatment Based on Organ-like Culture
- Conditions
- Interventions
- Drug: TrastuzumabDrug: Doxorubicin HydrochlorideDrug: Epirubicin hydrochlorideDrug: FluorouracilDrug: PaclitaxelDrug: GemcitabineDrug: CisplatinDrug: Recombinant Human EndostatinDrug: Pirarubicin hydrochlorideDrug: PyrrolidineDrug: IxabepiloneDrug: Tamoxifen citrateDrug: Vinorelbine tartrateDrug: CarboplatinDrug: MethotrexateDrug: Eribulin mesylateDrug: Toremifene citrateDrug: AnastrozoleDrug: LetrozoleDrug: ExemestaneDrug: FulvestrantDrug: OlaparibDrug: BevacizumabDrug: Apatinib mesylateDrug: PattozumabDrug: CapecitabineDrug: Ear particlesDrug: Aidi InjectionDrug: Cyclophosphamide
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2019-04-24
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT03925233
- Locations
- 🇨🇳
JingSu, Xi'an, Shaanxi, China
WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor
- Conditions
- Interventions
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 19
- Registration Number
- NCT03854903
- Locations
- 🇺🇸
Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer
- First Posted Date
- 2019-01-15
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT03803761
- Locations
- 🇺🇸
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸University of Texas Medical Branch, Galveston, Texas, United States
🇺🇸Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States
Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Conditions
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Sermonix Pharmaceuticals Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT03781063
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers, Longmont, Colorado, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸The Ohio State University - Comprehensive Cancer Center, Columbus, Ohio, United States
Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-12-11
- Last Posted Date
- 2023-03-07
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 59
- Registration Number
- NCT03772353
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-12-06
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Menarini Group
- Target Recruit Count
- 62
- Registration Number
- NCT03767335
- Locations
- 🇺🇸
Holy Cross Hospital Inc., Fort Lauderdale, Florida, United States
🇧🇪UZ Leuven, Leuven, Belgium
🇺🇸Detroit Clinical Research Center, Farmington Hills, Michigan, United States
Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis
- Conditions
- Interventions
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Emory University
- Target Recruit Count
- 38
- Registration Number
- NCT03691493
- Locations
- 🇺🇸
Grady Health System, Atlanta, Georgia, United States
🇺🇸Emory Saint Joseph's Hospital, Atlanta, Georgia, United States
🇺🇸Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-09-26
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 54
- Registration Number
- NCT03685331
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-08-22
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT03643510
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Commack, Commack, New York, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2021-10-15
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 93
- Registration Number
- NCT03633331
- Locations
- 🇺🇸
Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States
🇺🇸Saint Luke's Mountain States Tumor Institute - Nampa, Nampa, Idaho, United States
🇺🇸Kootenai Cancer Center, Post Falls, Idaho, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.